{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.30"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"21"}],"units":"Participants"}],"description":"The Maximum Tolerated Dose (MTD) will be defined as the highest safely-tolerated dose where at most one out of six patients experiences a Dose Limiting Toxicity (DLT) with the next higher dose level having at least 2 patients who have experienced DLT. The MTD determination will be based on DLT toxicities encountered during the first 8 weeks of treatment reported in Primary Outcome Measure #1.","groups":[{"description":"Dose Level 1= 0.15 mg/kg\\> Dose Level 2= 0.20 mg/kg\\> Dose Level 3= 0.30 mg/kg\\> Each cycle is 4 weeks.\\> \\> Cycle 1 and 2:\\> Alefacept by IV Weekly\\>\n\n\\> Cycles 3-12:\\> Alefacept by IV 1 x every 4 weeks","id":"OG000","title":"All Patients"}],"paramType":"NUMBER","populationDescription":"Two patients from Dose level 2 were not able to complete cycle 1 and were not evaluated for dose limiting toxicity.","reportingStatus":"POSTED","timeFrame":"8 weeks from registration","title":"Maximum Tolerated Dose (MTD)","type":"PRIMARY","unitOfMeasure":"mg/kg Alefacept"}